Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 6.4% – Should You Sell?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) traded down 6.4% during mid-day trading on Monday. The stock traded as low as $4.08 and last traded at $4.0820. 7,201,849 shares were traded during mid-day trading, a decline of 62% from the average session volume of 19,100,949 shares. The stock had previously closed at $4.36.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on RXRX. Morgan Stanley set a $5.30 price target on Recursion Pharmaceuticals in a research report on Monday, August 17th. Wall Street Zen raised Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 29th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Friday, July 17th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Recursion Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $8.06.

Recursion Pharmaceuticals Stock Performance

The company has a market cap of $2.13 billion, a PE ratio of -3.83 and a beta of 1.04. The company has a current ratio of 5.03, a quick ratio of 5.03 and a debt-to-equity ratio of 0.01. The firm’s 50-day simple moving average is $3.57 and its two-hundred day simple moving average is $3.39.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.01). The company had revenue of $7.67 million for the quarter, compared to analyst estimates of $10.97 million. Recursion Pharmaceuticals had a negative net margin of 945.94% and a negative return on equity of 50.41%. During the same quarter in the previous year, the company posted ($0.41) EPS. As a group, research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -0.94 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Robert Hershberg sold 25,000 shares of the firm’s stock in a transaction on Tuesday, October 6th. The stock was sold at an average price of $5.00, for a total value of $125,000.00. Following the completion of the transaction, the director owned 162,156 shares in the company, valued at $810,780. This trade represents a 13.36% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Blake Borgeson sold 50,000 shares of the firm’s stock in a transaction on Tuesday, October 6th. The stock was sold at an average price of $4.84, for a total value of $242,000.00. Following the completion of the transaction, the director owned 6,108,287 shares of the company’s stock, valued at $29,564,109.08. This trade represents a 0.81% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 157,408 shares of company stock valued at $643,576 over the last ninety days. 6.65% of the stock is currently owned by insiders.

Institutional Trading of Recursion Pharmaceuticals

Several large investors have recently added to or reduced their stakes in RXRX. MCF Advisors LLC acquired a new position in shares of Recursion Pharmaceuticals in the second quarter valued at about $27,000. Integral Investment Advisors Inc. purchased a new position in shares of Recursion Pharmaceuticals in the first quarter worth about $39,000. MQS Management LLC purchased a new position in shares of Recursion Pharmaceuticals in the first quarter worth about $41,000. Fund Advisors of America Inc FL acquired a new stake in shares of Recursion Pharmaceuticals during the second quarter worth about $45,000. Finally, Sequoia Financial Advisors LLC lifted its holdings in shares of Recursion Pharmaceuticals by 51.5% during the first quarter. Sequoia Financial Advisors LLC now owns 15,162 shares of the company’s stock worth $47,000 after purchasing an additional 5,156 shares during the period. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc is a clinical-stage biotechnology company that uses biology, chemistry, automation and machine learning to discover and develop new medicines. The company’s technology platform is designed to generate and analyze large volumes of biological and chemical data, helping researchers identify potential drug candidates and better understand disease mechanisms.

Recursion has focused its research and development activities on areas including oncology, rare diseases and neuroscience.